Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that educator John F. Thompson, MD, don of Melanoma and Surgical Oncology at the teaching hospital of Sydney, controller of the Melanoma principle Australia, and Lead sleuth of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on november 11 21, 2009 in Berlin, Germany.

More: - From the site